blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2593432

EP2593432 - N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.08.2015
Database last updated on 28.06.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Pfizer Limited
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
[2013/21]
Inventor(s)01 / BELL, Andrew, Simon
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
02 / BROWN, Alan, Daniel
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
03 / DE GROOT, Marcel, John
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
04 / GAULIER, Steven, Matthieu
c/o Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
05 / LEWTHWAITE, Russell, Andrew
c/o Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
06 / MARSH, Ian, Roger
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
07 / MILLAN, David, Simon
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
08 / PEREZ PACHECO, Manuel
c/o Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
09 / RAWSON, David, James
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
10 / SCIAMMETTA, Nunzio
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
11 / STORER, Robert, Ian
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
12 / SWAIN, Nigel, Alan
Pfizer Global Research and Development
Ramsgate Road
Sandwich
Kent CT13 9NJ / GB
 [2013/21]
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2013/21]
Application number, filing date11741280.924.06.2011
WO2011IB52797
Priority number, dateUS201161491659P31.05.2011         Original published format: US 201161491659 P
US201161477897P21.04.2011         Original published format: US 201161477897 P
US20100363365P12.07.2010         Original published format: US 363365 P
[2013/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012007861
Date:19.01.2012
Language:EN
[2012/03]
Type: A1 Application with search report 
No.:EP2593432
Date:22.05.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 19.01.2012 takes the place of the publication of the European patent application.
[2013/21]
Type: B1 Patent specification 
No.:EP2593432
Date:22.10.2014
Language:EN
[2014/43]
Search report(s)International search report - published on:EP19.01.2012
ClassificationIPC:C07D213/74, C07D213/85, C07D215/20, C07D231/56, C07D239/47, C07D401/04, C07D405/12, C07D487/04, C07B59/00, A61K31/44, A61P29/00
[2014/24]
CPC:
C07D213/69 (EP,US); A61P29/00 (EP); A61P43/00 (EP);
C07D213/63 (EP,US); C07D213/64 (EP,US); C07D213/65 (EP,US);
C07D213/70 (EP,US); C07D213/74 (EP,US); C07D213/85 (EP,US);
C07D215/20 (EP,US); C07D231/56 (EP,US); C07D239/47 (EP,US);
C07D401/04 (EP,US); C07D405/12 (EP,US); C07D487/04 (EP,US) (-)
Former IPC [2013/21]C07D213/63, C07D213/64, C07D213/65, C07D213/69, C07D213/70, C07D213/74, C07D213/85, C07D215/20, C07D231/56, C07D239/47, C07D401/04, C07D405/12, C07D487/04, C07B59/00, A61K31/44
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/21]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:N-SULFONYLBENZAMIDDERIVATE ALS SPANNUNGSGESTEUERTE NATRIUMKANALHEMMER[2013/21]
English:N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS[2013/21]
French:DÉRIVÉS DE N-SULFONYLBENZAMIDE UTILES COMME INHIBITEURS DU CANAL SODIQUE VOLTAGE-DÉPENDANT[2013/21]
Entry into regional phase12.02.2013National basic fee paid 
12.02.2013Designation fee(s) paid 
12.02.2013Examination fee paid 
Examination procedure12.02.2013Examination requested  [2013/21]
26.07.2013Amendment by applicant (claims and/or description)
22.11.2013Despatch of a communication from the examining division (Time limit: M06)
09.04.2014Reply to a communication from the examining division
17.06.2014Communication of intention to grant the patent
08.09.2014Fee for grant paid
08.09.2014Fee for publishing/printing paid
08.09.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.11.2013
Opposition(s)23.07.2015No opposition filed within time limit [2015/40]
Fees paidRenewal fee
01.07.2013Renewal fee patent year 03
30.06.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.06.2011
AL22.10.2014
AT22.10.2014
BE22.10.2014
BG22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
MK22.10.2014
MT22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SI22.10.2014
SK22.10.2014
SM22.10.2014
TR22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
LU24.06.2015
CH30.06.2015
LI30.06.2015
[2018/46]
Former [2018/31]HU24.06.2011
AT22.10.2014
BE22.10.2014
BG22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
MK22.10.2014
MT22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SI22.10.2014
SK22.10.2014
SM22.10.2014
TR22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
LU24.06.2015
CH30.06.2015
LI30.06.2015
Former [2017/46]HU24.06.2011
AT22.10.2014
BE22.10.2014
BG22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
MT22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SI22.10.2014
SK22.10.2014
SM22.10.2014
TR22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
LU24.06.2015
CH30.06.2015
LI30.06.2015
Former [2017/39]HU24.06.2011
AT22.10.2014
BG22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
MT22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SI22.10.2014
SK22.10.2014
SM22.10.2014
TR22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
LU24.06.2015
CH30.06.2015
LI30.06.2015
Former [2017/03]AT22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
MT22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SI22.10.2014
SK22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
LU24.06.2015
CH30.06.2015
LI30.06.2015
Former [2016/22]AT22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SI22.10.2014
SK22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
LU24.06.2015
CH30.06.2015
LI30.06.2015
Former [2016/11]AT22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SI22.10.2014
SK22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
LU24.06.2015
Former [2016/09]AT22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
MC22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SK22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/37]AT22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
SK22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/36]AT22.10.2014
CY22.10.2014
CZ22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
NL22.10.2014
PL22.10.2014
RO22.10.2014
RS22.10.2014
SE22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/35]AT22.10.2014
CY22.10.2014
DK22.10.2014
EE22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
NL22.10.2014
PL22.10.2014
RS22.10.2014
SE22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/26]AT22.10.2014
CY22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
NL22.10.2014
PL22.10.2014
RS22.10.2014
SE22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/25]AT22.10.2014
FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
NL22.10.2014
PL22.10.2014
RS22.10.2014
SE22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/24]FI22.10.2014
HR22.10.2014
LT22.10.2014
LV22.10.2014
NL22.10.2014
PL22.10.2014
RS22.10.2014
SE22.10.2014
NO22.01.2015
GR23.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/23]FI22.10.2014
LT22.10.2014
NL22.10.2014
NO22.01.2015
IS22.02.2015
PT23.02.2015
Former [2015/22]LT22.10.2014
NO22.01.2015
PT23.02.2015
Former [2015/21]LT22.10.2014
NO22.01.2015
Former [2015/20]LT22.10.2014
Cited inInternational search[X]EP0399732  (ICI PLC [GB]) [X] 1,8,10-14,17-19 * page 6, line 37 - line 39; example 16; claims 1,10 *;
 [X]JP2001075213  (FUJI PHOTO FILM CO LTD) [X] 1-5,8,10-14 * compounds I-11, I-42 *;
 [A]WO2009049181  (VERTEX PHARMA [US], et al) [A] 1-23 * paragraph [0260]; claims 1,19 *
by applicantWO2005013914
 WO2008118758
 WO2009012242
 US6106864
 WO0035298
 WO9111172
 WO9402518
 WO9855148
 WO2008135826
 WO2008047229
    - HUBNER CA, JENTSCH TJ, HUM. MOL. GENET., (2002), vol. 11, no. 20, pages 2435 - 45
    - YOGEESWARI ET AL., CURR. DRUG TARGETS, (2004), vol. 5, no. 7, pages 589 - 602
    - NOBLE D., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, no. 9, pages 5755 - 6
    - CANNON, SC, KIDNEY INT., (2000), vol. 57, no. 3, pages 772 - 9
    - WOOD, JN ET AL., J. NEUROBIOL., (2004), vol. 61, no. 1, pages 55 - 71
    - TOLEDO-ARAL ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, no. 4, pages 1527 - 1532
    - NASSAR ET AL., PROC NATL ACAD SCI USA, (2004), vol. 101, no. 34, pages 12706 - 11
    - KRETSCHMER ET AL., ACTA. NEUROCHIR. (WIEN, (2002), vol. 144, no. 8, pages 803 - 10
    - YANG ET AL., J. MED. GENET., (2004), vol. 41, no. 3, pages 171 - 4
    - WAXMAN, SG, NEUROLOGY, (20061207), vol. 69, no. 6, pages 505 - 7
    - LEGROUX-CREPEL ET AL., ANN. DERMATOL VENEREOL, vol. 130, pages 429 - 433
    - FERTLEMAN ET AL., NEURON, (2006), vol. 52, no. 5, pages 767 - 74
    - COX, NATURE, (2006), vol. 444, no. 7121, pages 894 - 8
    - GOLDBERG ET AL., CLIN GENET, (2007), vol. 71, no. 4, pages 311 - 9
    - AHMAD ET AL., HUM MOL GENET., (20061201), vol. 16, no. 17, pages 2114 - 21
    - O. ALMARSSON, M. J. ZAWOROTKO, CHEM COMMUN, (2004), vol. 17, pages 1889 - 1896
    - HALEBLIAN, J PHARM SCI, (197508), vol. 64, no. 8, pages 1269 - 1288
    - T HIGUCHI, W STELLA, "Pro-drugs as Novel Delivery Systems", ACS SYMPOSIUM SERIES, vol. 14
    - LIANG, CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, (2001), vol. 11, no. 6, pages 981 - 986
    - H. LIEBERMAN, L. LACHMAN, Pharmaceutical Dosage Forms: Tablets, MARCEL DEKKER, (1980), vol. 1
    - VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, (2001), vol. 25, no. 2, pages 1 - 14
    - FINNIN, MORGAN, J PHARM SCI, (199910), vol. 88, no. 10, pages 955 - 958
    - MILLAN, PROG. NEUROBIOL., (1999), vol. 57, pages 1 - 164
    - WOOLF, SALTER, SCIENCE, (2000), vol. 288, pages 1765 - 1768
    - MEYER ET AL., Textbook of Pain, (1994), pages 13 - 44
    - WOOLF, MANNION, LANCET, (1999), vol. 353, pages 1959 - 1964
    - WOOLF, DECOSTERD, PAIN, (1999), vol. 6, pages S141 - S147
    - LEVINE, TAIWO, Textbook of Pain, (1994), pages 45 - 56
    - GRENNAN, JAYSON, Textbook of Pain, (1994), pages 397 - 407
    - HOUGE, MERSFELDER, ANN PHARMACOTHER, (2002), vol. 36, pages 679 - 686
    - MCCARTHY ET AL., Textbook of Pain, (1994), pages 387 - 395
    - J. MED. CHEM., (1972), vol. 15, page 79
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.